— Results with the GIP/GLP -1 receptor agonist were statistically remarkable to included insulin lispro
by Kristen Monaco, Senior Staff Writer, MedPage Today
October 3, 2023
HAMBURG, Germany– Adding weekly tirzepatide (Mounjaro) to basal insulin minimized HbA1c in clients with improperly managed type 2 diabetes compared to including three-times-daily insulin lispro, the stage IIIb SURPASS-6 trial revealed.
In clients on an insulin glargine program, the approximated mean modification from standard in HbA1c at week 52 was -2.1% for those designated to among 3 various dosages of the double GIP/GLP -1 receptor agonist, as compared to -1.1% for those randomized to insulin lispro, leading to mean HbA1c levels of 6.7% versus 7.7% (P< 0.001), reported Juan P. Frías, MD, of Velocity Clinical Research in Los Angeles, throughout the European Association for the Study of Diabetes (EASD) yearly conference.
These outcomes satisfied noninferiority requirements, and analytical supremacy was attained, the authors composed in JAMAwhere the findings were likewise released.
Those who included tirzepatide had a more than 4 times greater opportunity of attaining an HbA1c under 7% (68% vs 36% in the insulin lispro group; OR 4.2, 95% CI 3.2-5.5)– satisfying an essential secondary endpoint.
In addition, clients taking tirzepatide had a mean weight-loss of 9 kg (19.9 pound) over 52 weeks, while those who included insulin lispro acquired 3.2 kg (7.1 pound).
“Tirzepatide showed medically significant and exceptional glycemic and body weight control versus insulin lispro and was connected with considerably less medically substantial hypoglycemia and less insulin usage,” Frías stated throughout his discussion.
The FDA authorized tirzepatide in May 2022 as a first-in-class treatment for type 2 diabetes. It has actually considering that shot to appeal for its off-label weight-loss abilities, showing as much as a 15.7% (34.4 pound) body weight-loss in a trial of clients with weight problems or obese and type 2 diabetes.
This trial marks the 6th installation of the SURPASS medical program. Formerly, the SURPASS-5 trial compared tirzepatide or placebo plus insulin glargine. All 3 dosages of tirzepatide– 5, 10, or 15 mg– yielded signific